5300 MEMORIAL DRIVE, HOUSTON, TX
Expands Global IP Portfolio with New Australian Patent for Annamycin
Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer
Shareholder Approval for Name Change to Moleculin Inc.
Announces Notice of Allowance for Canadian Patent Covering Annamycin
Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial
Investor Presentation
Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia
Announces Exercise of Warrants for $6.0 Million Gross Proceeds
Q2
Q1
Amended Annual Report
FY 2024
FY 2023 amended
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(4)
Amended Registration Statement for Securities
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Post-Effective Amendment to Registration Statement
Correspondence
Submission Upload